We, therefore, wanted to determine the expression and tau engagement of a tau-specific antibody, RNJ1, in a conventional immunoglobulin (IgG) format and as engineered scFv intrabody following IVT mRNA delivery to human neuroblastoma SH-SY5Y cells. This evidence concerns the gene MAPT and neuroblastoma.